Xiao Hang Tong
Chairman at Shanghai Cardimed Medical Technology Co. Ltd.
Profile
Xiao Hang Tong currently works at Shanghai Cardimed Medical Technology Co. Ltd., as Chairman from 2015, AnHeart Therapeutics (Hangzhou) Co., Ltd., as Chairman, Insight Lifetech Co., Ltd., as Non-Executive Director from 2017, and Lingke Pharmaceutical Hangzhou Co., Ltd., as Director from 2020.
Dr. Tong also formerly worked at Suzhou Decheng Life Science Venture Capital (Shanghai), as Vice President-Investment from 2014 to 2020.
Dr. Tong received his undergraduate degree in 2010 from Peking University, undergraduate degree in 2005 from the University of Science & Technology of China, and doctorate degree in 2010 from Chinese Academy of Sciences.
Xiao Hang Tong active positions
| Companies | Position | Start |
|---|---|---|
Insight Lifetech Co., Ltd.
 Insight Lifetech Co., Ltd. Medical SpecialtiesHealth Technology Insight Lifetech Co., Ltd. engages in the manufacture and sale of interventional cardiovascular diagnostic and therapy products. It offers exchange fractional flow reserve (FFR) microcatheters, cardiovascular pressure measurement (CPM) systems, intravascular ultrasound systems, and microcatheters for complex percutaneous coronary intervention (PCI). The company was founded by Xiao Yang Fu and Li Li Chen on December 11, 2015 and is headquartered in Shenzhen, China. | Director/Board Member | 2017-06-20 |
Shanghai Cardimed Medical Technology Co. Ltd.
 Shanghai Cardimed Medical Technology Co. Ltd. Medical DistributorsDistribution Services Shanghai Cardimed Medical Technology Co. Ltd. is a company that distributes hemodialysis and renal care equipment. The company was founded in 2015 and is based in Shanghai, China. | Chairman | 2015-09-30 |
| Lingke Pharmaceutical Hangzhou Co., Ltd. | Director/Board Member | 2020-01-31 |
AnHeart Therapeutics (Hangzhou) Co., Ltd.
 AnHeart Therapeutics (Hangzhou) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services AnHeart Therapeutics (Hangzhou) Co., Ltd. engages in the development of pharmaceutical products. Its offers neurotrophic tyrosine receptor kinase and c-ros oncogene 1 dual-target inhibitors for cancer treatment. The company was founded by Jun Yuan Wang, Bing Yan and Li Hua Zheng on November 27, 2018 and is headquartered in Hangzhou, China. | Chairman | - |
Former positions of Xiao Hang Tong
| Companies | Position | End |
|---|---|---|
| Suzhou Decheng Life Science Venture Capital (Shanghai) | Chief Investment Officer | 2020-04-30 |
Training of Xiao Hang Tong
| University of Science & Technology of China | Undergraduate Degree |
| Peking University | Undergraduate Degree |
| Chinese Academy of Sciences | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Insight Lifetech Co., Ltd.
Insight Lifetech Co., Ltd. Medical SpecialtiesHealth Technology Insight Lifetech Co., Ltd. engages in the manufacture and sale of interventional cardiovascular diagnostic and therapy products. It offers exchange fractional flow reserve (FFR) microcatheters, cardiovascular pressure measurement (CPM) systems, intravascular ultrasound systems, and microcatheters for complex percutaneous coronary intervention (PCI). The company was founded by Xiao Yang Fu and Li Li Chen on December 11, 2015 and is headquartered in Shenzhen, China. | Health Technology |
Shanghai Cardimed Medical Technology Co. Ltd.
Shanghai Cardimed Medical Technology Co. Ltd. Medical DistributorsDistribution Services Shanghai Cardimed Medical Technology Co. Ltd. is a company that distributes hemodialysis and renal care equipment. The company was founded in 2015 and is based in Shanghai, China. | Distribution Services |
| Lingke Pharmaceutical Hangzhou Co., Ltd. | |
| Suzhou Decheng Life Science Venture Capital (Shanghai) | |
AnHeart Therapeutics (Hangzhou) Co., Ltd.
AnHeart Therapeutics (Hangzhou) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services AnHeart Therapeutics (Hangzhou) Co., Ltd. engages in the development of pharmaceutical products. Its offers neurotrophic tyrosine receptor kinase and c-ros oncogene 1 dual-target inhibitors for cancer treatment. The company was founded by Jun Yuan Wang, Bing Yan and Li Hua Zheng on November 27, 2018 and is headquartered in Hangzhou, China. | Commercial Services |
- Stock Market
- Insiders
- Xiao Hang Tong